Series C funding round for Escient Pharmaceuticals raising $120M in November 2022
Series C funding round for Escient Pharmaceuticals raising $120M in November 2022
| Investor | Firm Type | Partner |
|---|
AbingworthLEAD | Venture Capital | — |
NEALEAD | Venture Capital | — |
| Venture Capital | — | |
| Private | — | |
| Venture Capital | — | |
| Venture Capital | — | |
| Venture Capital | — | |
| Venture Capital | — | |
| Venture Capital | — | |
| Venture Capital | — | |
| Venture Capital | — | |
| Corporate Venture Capital | — | |
| Venture Capital | — | |
| Venture Capital | — | |
| Venture Capital | — | |
| Hedge Fund | — | |
| Venture Capital | — | |
| Angel | Robert Garland | |
| Angel | Carol Gallagher |
This company has completed 3 funding rounds. Current round is highlighted.
Total Raised
$238M
Top Valuation
-
Escient Pharmaceuticals raised $120M in a Series C round.
The round was announced on 11/01/22.
The round was led by Abingworth, Forge Life Science Partners, NEA.